EANS-Adhoc: Intercell AG / Intercell starts clinical trial in Pandemic Influenza with its Vaccine Enhancement Patch and provides update to the strategic collaboration with GSK on patches

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

04.05.2011

» Intercell starts a confirmatory clinical study using the Vaccine Enhancement
Patch in combination with GSK's H5N1 pandemic Influenza antigen
» GSK and Intercell underline their commitment to advancing the value of the
patch technology in the research & development of patch delivered vaccines.

Vienna (Austria), May 04, 2011 - Today Intercell AG (VSE: ICLL) announced the
start of a further trial in the field of pandemic Influenza, investigating
Intercell's adjuvant patch (Vaccine Enhancement Patch - VEP) containing LT (a
heat-labile toxin from E. coli) in combination with GSK's H5N1 pandemic antigen.
This trial follows prior work with a non-GSK pandemic Influenza antigen carried
out by Intercell under its contract with the U.S. Department of Health and Human
Services (HHS) to develop a dose-sparing approach with potential for a single
dose immunization.

The confirmatory trial will be performed under a Phase I protocol due to the
introduction of a different H5N1 antigen. The study will involve 300 healthy
adults and investigate various combinations of antigen and patch doses in one
and two injection regimes to confirm mode of action and the value of "external"
adjuvantation. GSK's adjuvanted and licensed H5N1 vaccine will be used to
provide a positive control for the patch and GSK's well established and
validated H5N1 hemagglutination inhibition (HI) assay will be applied.

Intercell and GSK have maintained their commitment to continue to explore the
value of the patch technology and will focus on evaluating the use of the patch
technology for transcutaneous vaccination with existing or new antigens.
Following the discontinuation of the Travelers' Diarrhea (TD) patch vaccine
program as announced at the end of 2010, Intercell and GSK have mutually
terminated the respective marketing and distribution collaboration. On this
basis, all rights on the TD patch vaccine revert back to Intercell. Based on the
clinical efficacy data obtained against LT-positive enterotoxigenic E. coli
(ETEC) the company will continue to evaluate the potential of the vaccine
candidate especially for endemic countries.

"We are pleased to continue our partnership with GSK to accelerate the
development of needle?free, patch?based vaccines. We are also looking forward to
investigating further the potential of our Vaccines Enhancement Patch (VEP) with
this confirmatory clinical study in our pandemic Influenza program," stated
Thomas Lingelbach, Chief Operating Officer of Intercell.

Further inquiry note:
Intercell AG
Nina Waibel
Corporate Communications
Tel. +43 1 20620-1222
[email protected]
end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer:      Intercell AG
             Campus Vienna Biocenter  3
             A-1030 Wien 
phone:       +43 1 20620-0
FAX:         +43 1 20620-800
mail:        [email protected] 
WWW:         www.intercell.com
sector:      Biotechnology
ISIN:        AT0000612601
indexes:     ATX Prime, ATX

stockmarkets: official market: Wien
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | OTB

print